

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 9/54 // C11D 3/386</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/37621</b> (43) International Publication Date: 29 June 2000 (29.06.00)
<p>(21) International Application Number: PCT/DK99/00711</p> <p>(22) International Filing Date: 20 December 1999 (20.12.99)</p> <p>(30) Priority Data: PA 1998 01677 18 December 1998 (18.12.98) DK PA 1999 00706 20 May 1999 (20.05.99) DK</p> <p>(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).</p> <p>(72) Inventors: ANDERSEN VILBOUR, Kim; Tåsingegade 31 4.th., DK-2100 Copenhagen Ø. (DK). MIKKELSEN, Frank; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK). HANSEN KAMP, Peter; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK). ANDERSEN, Carsten; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK). NØRREGAARD-MADSEN, Mads; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd (DK).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: SUBTILASE ENZYMES OF THE I-S1 AND I-S2 SUB-GROUPS HAVING AN ADDITIONAL AMINO ACID RESIDUE IN AN ACTIVE SITE LOOP REGION</p> <p>(57) Abstract</p> <p>Subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid residue in position 98 of the active site loop (b) region from position 95 to 103. Variant subtilases exhibit improved wash performance in a detergent in comparison to its parent enzyme.</p> <p><b>BEST AVAILABLE COPY</b></p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: Subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid residue in an active site loop region.

#### TECHNICAL FIELD

5 This invention relates to novel subtilase enzymes of the I-S1 and I-S2 sub-groups having at least one additional amino acid residue in position 98 of the active site loop (b) region from position 95 to 103. These proteases are useful exhibiting excellent or improved wash performance when used in detergents;  
10 cleaning and detergent compositions. The invention further relates to genes coding for the expression of said enzymes when inserted into a suitable host cell or organism; and such host cells transformed therewith and capable of expressing said enzyme variants, and methods for producing the novel enzymes.

15

#### BACKGROUND OF THE INVENTION

In the detergent industry enzymes have for more than 30 years been implemented in washing formulations. Enzymes used in  
20 such formulations comprise proteases, lipases, amylases, cellulases, as well as other enzymes, or mixtures thereof. Commercially most important enzymes are proteases.

An increasing number of commercially used proteases are protein engineered variants of naturally occurring wild type  
25 proteases, e.g. DURAZYM<sup>®</sup> (Novo Nordisk A/S), RELEASE<sup>®</sup> (Novo Nordisk A/S), MAXAPEM<sup>®</sup> (Gist-Brocades N.V.), PURAFECT<sup>®</sup> (Genencor International, Inc.).

Further a number of protease variants are described in the art, such as in EP 130756 (GENENTECH) (corresponding to US  
30 Reissue Patent No. 34,606 (GENENCOR)); EP 214435 (HENKEL); WO 87/04461 (AMGEN); WO 87/05050 (GENEX); EP 260105 (GENENCOR); Thomas, Russell, and Fersht (1985) *Nature* 318 375-376; Thomas,

Russell, and Fersht (1987) *J. Mol. Biol.* 193 803-813; Russel and Fersht *Nature* 328 496-500 (1987); WO 88/08028 (Genex); WO 88/08033 (Amgen); WO 95/27049 (SOLVAY S.A.); WO 95/30011 (PROCTER & GAMBLE COMPANY); WO 95/30010 (PROCTER & GAMBLE COMPANY); WO 95/29979 (PROCTER & GAMBLE COMPANY); US 5.543.302 (SOLVAY S.A.); EP 251 446 (GENENCOR); WO 89/06279 (NOVO NORDISK A/S); WO 91/00345 (NOVO NORDISK A/S); EP 525 610 A1 (SOLVAY); and WO 94/02618 (GIST-BROCADES N.V.).

However, even though a number of useful protease variants have been described, there is still a need for new improved proteases or protease variants for a number of industrial uses.

Therefore, an object of the present invention, is to provide improved proteases or protein engineered protease variants, especially for use in the detergent industry.

15

#### SUMMARY OF THE INVENTION

The present inventors have found that subtilisins wherein at least one of the active site loops are longer than those presently known, exhibit improved wash performance properties in detergent compositions. The identification thereof was done in constructing subtilisin variants, especially of the subtilisin 309 (BLSAVI or Savinase®), exhibiting improved wash performance properties in detergent compositions relative to the parent wild type enzyme. This has been described in our earlier application DK1332/97.

It has now been found that certain subtilases or variants thereof of the I-S1 (true "subtilisins") and I-S2 (high alkaline subtilisins) sub-groups having at least one additional amino acid residue in position 98 (or rather between positions 98 and 99) of the active site loop (b) region from position 95 to 103, exhibit surprisingly improved wash performance in

comparison to those presently known and those described in said application.

The improved proteases according to the invention may be obtained by isolation from natural resources or by the introduction of at least one further amino acid residue (an insertion) in the active site loop (b) between positions 98 and 99 in a wild type subtilase (for a definition of the active site loops and the numbering of positions see below).

Although this finding was done in subtilisin 309 it is predicted that it will be possible to produce or isolate similar advantageous subtilases or subtilase variants.

Furthermore it will be possible to specifically screen natural isolates to identify novel wild type subtilases comprising an active site loop (b) which is longer than the corresponding active site loop in known wild type subtilases, such as subtilisin 309, which subtilases can be considered to have an inserted amino acid residue between positions 98 and 99, and exhibiting excellent wash performance in a detergent, in comparison to their closest related known subtilisin, such as subtilisin 309.

Concerning alignment and numbering reference is made to Figs. 1, 1a, 2 and 2a below showing alignments between subtilisin BPN' (BASBPN) (a) and subtilisin 309 (BLSAVI) (b), and alignments between subtilisin BPN' (a) (BASBPN) and subtilisin Carlsberg (g). In Figs. 1 and 2 the alignments were established by the use of the GAP routine of the GCG package as indicated below, whereas the alignments of Figs. 1a and 2a are the same as shown in WO 91/00345. These alignments are in this patent application used as a reference for numbering the residues.

The seven active site loops (a) to (g) (including both the end amino acid residues indicated) are here defined to encompass the amino acid residues in the segments given below

- (a) the region between amino acid residue 33 and 43;
- (b) the region between amino acid residue 95 and 103;
- (c) the region between amino acid residue 125 and 132;
- 5 (d) the region between amino acid residue 153 and 173;
- (e) the region between amino acid residue 181 and 195;
- (f) the region between amino acid residue 202 and 204;
- (g) the region between amino acid residue 218 and 219.

10 Accordingly, in a first aspect the invention relates to an isolated (i.e. greater than 10 % pure) subtilase enzymes of the I-S1 and I-S2 sub-groups having at least one additional amino acid residue in position 98 of the active site loop (b) region from position 95 to 103, whereby said additional amino  
15 acid residue(s) correspond to the insertion of at least one amino acid residue between positions 98 and 99.

In a second aspect the invention relates to an isolated DNA sequence encoding a subtilase variant of the invention.

In a third aspect the invention relates to an expression  
20 vector comprising an isolated DNA sequence encoding a subtilase variant of the invention.

In a fourth aspect the invention relates to a microbial host cell transformed with an expression vector according to the fourth aspect.

25 In a further aspect the invention relates to the production of the subtilisin enzymes of the invention.

The enzymes of the invention can generally be produced by either cultivation of a microbial strain from which the enzyme was isolated and recovering the enzyme in substantially pure  
30 form; or by inserting an expression vector according to the fourth aspect of the invention into a suitable microbial host,

cultivating the host to express the desired subtilase enzyme, and recovering the enzyme product.

Further the invention relates to a composition comprising a subtilase or subtilase variant of the invention.

5 Even further the invention relates to the use of the enzymes of the invention for a number of industrial relevant uses, in particular for use in cleaning compositions and cleaning compositions comprising the mutant enzymes, especially detergent compositions comprising the mutant subtilisin enzymes.

10

#### DEFINITIONS

Prior to discussing this invention in further detail, the following terms and conventions will first be defined.

NOMENCLATURE OF AMINO ACIDS

A	=	Ala	=	Alanine
V	=	Val	=	Valine
L	=	Leu	=	Leucine
5 I	=	Ile	=	Isoleucine
P	=	Pro	=	Proline
F	=	Phe	=	Phenylalanine
W	=	Trp	=	Tryptophan
M	=	Met	=	Methionine
10 G	=	Gly	=	Glycine
S	=	Ser	=	Serine
T	=	Thr	=	Threonine
C	=	Cys	=	Cysteine
Y	=	Tyr	=	Tyrosine
15 N	=	Asn	=	Asparagine
Q	=	Gln	=	Glutamine
D	=	Asp	=	Aspartic Acid
E	=	Glu	=	Glutamic Acid
K	=	Lys	=	Lysine
20 R	=	Arg	=	Arginine
H	=	His	=	Histidine
X	=	Xaa	=	Any amino acid

NOMENCLATURE OF NUCLEIC ACIDS

25 A	=	Adenine
G	=	Guanine
C	=	Cytosine
T	=	Thymine (only in DNA)
U	=	Uracil (only in RNA)

30

NOMENCLATURE AND CONVENTIONS FOR DESIGNATION OF VARIANTS



In describing the various enzyme variants produced or contemplated according to the invention, the following nomenclatures and conventions have been adapted for ease of reference:

5       A frame of reference is first defined by aligning the isolated or parent wild type enzyme with subtilisin BPN' (BASBPN).

The alignment can be obtained by the GAP routine of the GCG package version 9.1 to number the variants using the  
10 following parameters: gap creation penalty = 8 and gap extension penalty = 8 and all other parameters kept at their default values.

Another method is to use known recognised alignments between subtilases, such as the alignment indicated in WO  
15 91/00345. In most cases the differences will not be of any importance.

Such alignments between subtilisin BPN' (BASBPN) and subtilisin 309 (BLSAVI) and subtilisin Carlsberg (BLSCAR), respectively are indicated in Figs. 1, 1a, 2, and 2a. By this a  
20 number of deletions and insertions will be defined in relation to BASBPN. In Fig. 1 subtilisin 309 has 6 deletions in positions 36, 58, 158, 162, 163, and 164 in comparison to BASBPN, whereas in Fig. 1a subtilisin 309 has the same deletions in positions 36, 56, 159, 164, 165, and 166 in comparison to BASBPN. In Fig.  
25 2 subtilisin Carlsberg has one deletion in position 58 in comparison to BASBPN, whereas in Fig. 2a subtilisin Carlsberg has the one deletion in position 56 in comparison to BASBPN. These deletions are in Figs. 1, 1a, 2, and 2a indicated by asterixes (\*).

30       The various modifications performed in a wild type enzyme is indicated in general using three elements as follows:

Original amino acid position substituted amino acid

The notation G195E thus means a substitution of a glycine in position 195 with a glutamic acid.

5 In the case when the original amino acid residue may be any amino acid residue, a short hand notation may at times be used indicating only the position and substituted amino acid,

Position substituted amino acid

10

Such a notation is particular relevant in connection with modification(s) in homologous subtilases (*vide infra*).

Similarly when the identity of the substituting amino acid residue(s) is immaterial,

15

Original amino acid position

When both the original amino acid(s) and substituted amino acid(s) may comprise any amino acid, then only the position is indicated, e.g.: 170.

When the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), then the selected amino acids are indicated inside brackets { },

25 Original amino acid position {substituted amino acid<sub>1</sub>, . . . ,  
substituted amino acid<sub>n</sub>}

For specific variants the specific three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue.

30

SUBSTITUTIONS:

The substitution of Glutamic acid for glycine in position 195 is designated as:

Gly195Glu or G195E

or the substitution of any amino acid residue acid for glycine s in position 195 is designated as:

Gly195Xaa or G195X

or

Gly195 or G195

10 The substitution of serine for any amino acid residue in position 170 would thus be designated

Xaa170Ser or X170S.

or

170Ser or 170S

15

Such a notation is particular relevant in connection with modification(s) in homologous subtilases (*vide infra*). 170Ser is thus meant to comprise e.g. both a Lys170Ser modification in BASBPN and Arg170Ser modification in BLSAVI (cf. Fig. 1).

20 For a modification where the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), the substitution of glycine, alanine, serine or threonine for arginine in position 170 would be indicated by

25 Arg170{Gly,Ala,Ser,Thr} or R170{G,A,S,T}

to indicate the variants

R170G, R170A, R170S, and R170T.

#### DELETIONS:

30 A deletion of glycine in position 195 will be indicated by:

Gly195\* or G195\*

Correspondingly the deletion of more than one amino acid residue, such as the deletion of glycine and leucine in positions 195 and 196 will be designated

Gly195\*+Leu196\* or G195\*+L196\*

5

#### INSERTIONS:

The insertion of an additional amino acid residue such as e.g. a lysine after G195 is :

Gly195GlyLys or G195GK; or

10 when more than one amino acid residue is inserted, such as e.g. a Lys, Ala and Ser after G195 this is :

Gly195GlyLysAlaSer or G195GKAS

15 In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example the sequences 194 to 196 would thus be:

20	194 195 196
BLSAVI	A - G - L
	194 195 195a 195b 195c 196
Variant	A - G - K - A - S - L

25 In cases where an amino acid residue identical to the existing amino acid residue is inserted it is clear that a degeneracy in the nomenclature arises. If for example a glycine is inserted after the glycine in the above example this would be indicated by G195GG. The same actual change could just as well  
30 be indicated as A194AG for the change from

	194 195 196
BLSAVI	A - G - L

to

	194	195	195a	196
Variant	A	- G -	G -	L
	194	194a	195	196

5

Such instances will be apparent to the skilled person, and the indication G195GG and corresponding indications for this type of insertions are thus meant to comprise such equivalent degenerate indications.

10

#### FILLING A GAP:

Where a deletion in an enzyme exists in the reference comparison with the subtilisin BPN' sequence used for the numbering, an insertion in such a position is indicated as:

15

\*36Asp or \*36D

for the insertion of an aspartic acid in position 36

#### MULTIPLE MODIFICATIONS

20 Variants comprising multiple modifications are separated by pluses, e.g.:

Arg170Tyr+Gly195Glu or R170Y+G195E

representing modifications in positions 170 and 195 substituting tyrosine and glutamic acid for arginine and glycine, respectively.

25

or e.g. Tyr167{Gly,Ala,Ser,Thr}+Arg170{Gly,Ala,Ser,Thr} designates the variants

30

Tyr167Gly+Arg170Gly,	Tyr167Gly+Arg170Ala,
Tyr167Gly+Arg170Ser,	Tyr167Gly+Arg170Thr,
Tyr167Ala+Arg170Gly,	Tyr167Ala+Arg170Ala,
Tyr167Ala+Arg170Ser,	Tyr167Ala+Arg170Thr,
Tyr167Ser+Arg170Gly,	Tyr167Ser+Arg170Ala,
Tyr167Ser+Arg170Ser,	Tyr167Ser+Arg170Thr,

Tyr167Thr+Arg170Gly, Tyr167Thr+Arg170Ala,  
Tyr167Thr+Arg170Ser, and Tyr167Thr+Arg170Thr.

This nomenclature is particularly relevant relating to modifications aimed at substituting, replacing, inserting or deleting amino acid residues having specific common properties, such as residues of positive charge (K, R, H), negative charge (D, E), or conservative amino acid modification(s) of e.g. Tyr167{Gly,Ala,Ser,Thr}+Arg170{Gly,Ala,Ser,Thr}, which signifies substituting a small amino acid for another small amino acid.

10 See section "Detailed description of the invention" for further details.

#### Proteases

Enzymes cleaving the amide linkages in protein substrates are classified as proteases, or (interchangeably) peptidases (see Walsh, 1979, *Enzymatic Reaction Mechanisms*. W.H. Freeman and Company, San Francisco, Chapter 3).

#### Numbering of amino acid positions/residues

20 If nothing else is mentioned the amino acid numbering used herein correspond to that of the subtilase BPN<sup>-</sup> (BASBPN) sequence. For further description of the BPN<sup>-</sup> sequence see Figs. 1 and 2, or Siezen et al., *Protein Engng.* 4 (1991) 719-737.

#### 25 Serine proteases

A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site (White, Handler and Smith, 1973 "Principles of Biochemistry," Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).

The bacterial serine proteases have molecular weights in the 20,000 to 45,000 Dalton range. They are inhibited by

diisopropylfluorophosphate. They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest (1977) *Bacteriological Rev.* 41 711-753).

### Subtilases

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al., *Protein Engng.* 4 (1991) 719-737 and Siezen et al. *Protein Science* 6 (1997) 501-523. They are defined by homology analysis of more than 170 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously often defined as a serine protease produced by Gram-positive bacteria or fungi, and according to Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases has been determined. For a more detailed description of such subtilases and their amino acid sequences reference is made to Siezen et al. (1997).

One subgroup of the subtilases, I-S1 or "true# subtilisins", comprises the "classical" subtilisins, such as subtilisin 168 (BSS168), subtilisin BPN', subtilisin Carlsberg (ALCALASE<sup>®</sup>, NOVO NORDISK A/S), and subtilisin DY (BSSDY).

A further subgroup of the subtilases, I-S2 or high alkaline subtilisins, is recognised by Siezen et al. (*supra*). Sub-group I-S2 proteases are described as highly alkaline subtilisins and comprises enzymes such as subtilisin PB92 (BAALKP) (MAXACAL<sup>®</sup>, Gist-Brocades NV), subtilisin 309 (SAVINASE<sup>®</sup>, NOVO NORDISK A/S), subtilisin 147 (BLS147) (ESPERASE<sup>®</sup>, NOVO NORDISK A/S), and alkaline elastase YaB (BSEYAB).

List of acronyms for subtilases:

## I-S1

Subtilisin 168, BSS168 (BSSAS (Subtilisin amylosacchariticus),  
5 BSAPRJ (Subtilisin J), BSAPRN (Subtilisin NAT), BMSAMP  
(Mesentericopeptidase),  
Subtilisin BPN', BASBPN,  
Subtilisin DY, BSSDY,  
Subtilisin Carlsberg, BLSCAR (BLKERA (Keratinase), BLSCA1,  
10 BLSCA2, BLSCA3),  
BSSPRC, Serine protease C  
BSSPRD, Serine protease D

## I-S2

15 Subtilisin Sendai, BSAPRS  
Subtilisin ALP 1, BSAPRQ,  
Subtilisin 147, Esperase® BLS147 (BSAPRM (SubtilisinAprM),  
BAH101),  
Subtilisin 309, Savinase®, BLS309/BLSAVI (BSKSMK (M-protease),  
20 BAALKP (Subtilisin PB92, Bacillus alkalophilic alkaline  
protease), BLSUBL (Subtilisin BL)),  
Alkaline elastase YaB, BYSYAB,

## 25 "SAVINASE®"

SAVINASE® is marketed by NOVO NORDISK A/S. It is  
subtilisin 309 from B. Lentus and differs from BAALKP only in  
one position (N87S, see Fig. 1 herein). SAVINASE® has the amino  
acid sequence designated b) in Fig. 1.

30

Parent subtilase



The term "parent subtilase" describes a subtilase defined according to Siezen et al. (1991 and 1997). For further details see description of "SUBTILASES" immediately above. A parent subtilase may also be a subtilase isolated from a natural source, wherein subsequent modification have been made while retaining the characteristic of a subtilase. Alternatively the term "parent subtilase" may be termed "wild type subtilase".

#### Modification(s) of a subtilase variant

10       The term "modification(s)" used herein is defined to include chemical modification of a subtilase as well as genetic manipulation of the DNA encoding a subtilase. The modification(s) can be replacement(s) of the amino acid side chain(s), substitution(s), deletion(s) and/or insertions in or  
15 at the amino acid(s) of interest.

#### Subtilase variant

In the context of this invention, the term subtilase variant or mutated subtilase means a subtilase that has been  
20 produced by an organism which is expressing a mutant gene derived from a parent microorganism which possessed an original or parent gene and which produced a corresponding parent enzyme, the parent gene having been mutated in order to produce the mutant gene from which said mutated subtilase protease is  
25 produced when expressed in a suitable host.

#### Homologous subtilase sequences

Specific active site loop regions, and amino acid insertions in said loops of SAVINASE® subtilase are identified  
30 for modification herein to obtain a subtilase variant of the invention.

However, the invention is not limited to modifications of this particular subtilase, but extend to other parent (wild-type) subtilases, which have a homologous primary structure to that of SAVINASE®. The homology between two amino acid sequences is in this context described by the parameter "identity".

In order to determine the degree of identity between two subtilases the GAP routine of the GCG package version 9.1 can be applied (*infra*) using the same settings. The output from the routine is besides the amino acid alignment the calculation of the "Percent Identity" between the two sequences.

Based on this description it is routine for a person skilled in the art to identify suitable homologous subtilases and corresponding homologous active site loop regions, which can be modified according to the invention.

15

#### Wash performance

The ability of an enzyme to catalyze the degradation of various naturally occurring substrates present on the objects to be cleaned during e.g. wash or hard surface cleaning is often referred to as its washing ability, wash-ability, detergency, or wash performance. Throughout this application the term wash performance will be used to encompass this property.

#### Isolated DNA sequence

The term "isolated", when applied to a DNA sequence molecule, denotes that the DNA sequence has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of

other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985). The term "an isolated DNA sequence" may alternatively be termed "a cloned DNA sequence".

#### Isolated protein

10           When applied to a protein, the term "isolated" indicates that the protein has been removed from its native environment.

          In a preferred form, the isolated protein is substantially free of other proteins, particularly other homologous proteins (i.e. "homologous impurities" (see below)).

15           An isolated protein is greater than 10 % pure, preferably greater than 20 % pure, more preferably greater than 30 % pure, as determined by SDS-PAGE. Further it is preferred to provide the protein in a highly purified form, i.e., greater than 40% pure, greater than 60% pure, greater than 80% pure, more  
20 preferably greater than 95% pure, and even more preferably greater than 99% pure, as determined by SDS-PAGE.

          The term "isolated protein" may alternatively be termed "purified protein".

#### 25 Homologous impurities

          The term "homologous impurities" means any impurity (e.g. another polypeptide than the polypeptide of the invention) which originate from the homologous cell where the polypeptide of the invention is originally obtained from.

Obtained from

The term "obtained from" as used herein in connection with a specific microbial source, means that the polynucleotide and/or polypeptide produced by the specific source, or by a cell in which a gene from the source has been inserted.

Substrate

The term "Substrate" used in connection with a substrate for a protease is should be interpreted in its broadest form as comprising a compound containing at least one peptide bond susceptible to hydrolysis by a subtilisin protease.

Product

The term "product" used in connection with a product derived from a protease enzymatic reaction should in the context of this invention be interpreted to include the products of a hydrolysis reaction involving a subtilase protease. A product may be the substrate in a subsequent hydrolysis reaction.

20 BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 shows an alignment between subtilisin BPN' (a) and Savinase® (b) using the GAP routine mentioned above.

Fig. 1a shows the alignment between subtilisin BPN' and Savinase® as taken from WO 91/00345.

25 Fig. 2 shows an alignment between subtilisin BPN' and subtilisin Carlsberg using the GAP routine mentioned above.

Fig. 2a shows the alignment between subtilisin BPN' and subtilisin Carlsberg as taken from WO 91/00345.

Fig. 3 shows the three dimensional structure of Savinase  
30 (Protein data bank (PDB) entry 1SVN). In the Figure the active site loop (b) is indicated.

DETAILED DESCRIPTION OF THE INVENTION

The subtilases of the invention in a first aspect relates to an isolated (i.e. greater than 10 % pure) subtilase enzyme of the I-S1 and I-S2 sub-groups having at least one additional amino acid residue in position 98 of the active site loop (b) region from position 95 to 103, whereby said additional amino acid residue(s) correspond to the insertion of at least one amino acid residue between positions 98 and 99.

In other words the subtilases of the invention are characterized by comprising an active site loop (b) region of more than 9 amino acid residue and wherein the additional amino acid residue is or can be considered as being inserted between positions 98 and 99 as compared to the parent or a known wild type subtilase.

A subtilase of the first aspect of the invention may be a parent or wildtype subtilase identified and isolated from nature.

Such a parent wildtype subtilase may be specifically screened for by standard techniques known in the art.

One preferred way of doing this may be by specifically PCR amplify DNA regions known to encode active site loops in subtilases from numerous different microorganism, preferably different *Bacillus* strains.

Subtilases are a group of conserved enzymes, in the sense that their DNA and amino acid sequences are homologous. Accordingly it is possible to construct relatively specific primers flanking active site loops.

One way of doing this is by investigating an alignment of different subtilases (see e.g. Siezen et al. *Protein Science* 6 (1997) 501-523). It is from this routine work for a person skilled in the art to construct PCR primers flanking the active site loop corresponding to the active site loop (b) between

amino acid residue 95 to 103 in any of the group I-S1 or I-S2 groups, such as from BLSAVI. Using such PCR primers to amplify DNA from a number of different microorganism, preferably different Bacillus strains, followed by DNA sequencing of said amplified PCR fragments, it will be possible to identify strains which produce subtilases of these groups comprising a longer, as compared to e.g. BLSAVI, active site region corresponding to the active site loop region from positions 95 to 103, and where an insertion can be considered to exist between positions 98 and 99. Having identified the strain and a partial DNA sequence of such a subtilase of interest, it is routine work for a person skilled in the art to complete cloning, expression and purification of such a subtilase of the invention.

However, it is envisaged that a subtilase enzyme of the invention predominantly is a variant of a parent subtilase.

Accordingly, in one embodiment the invention relates to an isolated subtilase enzyme according to the first aspect of the invention, wherein said subtilase enzyme is a constructed variant having a longer active site loop (b) than its parent enzyme by having at least one amino acid insertion between amino acid residues 98 and 99.

The subtilases of the invention exhibit excellent wash performance in a detergent, and if the enzyme is a constructed variant an improved wash performance in a detergent in comparison to its closest related subtilase, such as subtilisin 309.

Different subtilase products will exhibit a different wash performance in different types of detergent compositions. A subtilase of the invention has improved wash performance, as compared to its closest relative in a majority of such different types of detergent compositions.

Preferably a subtilase enzyme of the invention has improved wash performance, as compared to its closest relative in the detergent composition shown in Example 3 herein (*vide infra*).

5 In order to determine if a given subtilase amino acid sequence (irrelevant whether said subtilase sequence is a parent wildtype subtilase sequence or a subtilase variant sequence produced by any other method than by site directed mutagenesis) is within the scope of the invention, the following procedure  
10 may be used:

- i) align said subtilase sequence to the amino acid sequence of subtilisin BPN' (see section "Definitions" herein (*vide supra*);
- ii) based on the alignment performed in step i) identify the  
15 active site loop (b), in said subtilase sequence corresponding to the active site loop (b) region of subtilisin BPN' comprising the region (both of the end amino acids included) between amino acid residue from 95 to 103;
- 20 iii) determine if the active site loop (b) in said subtilase sequence, identified in step ii) is longer than the corresponding active site loop in BLSAVI and if said prolongation corresponds to the insertion of at least one amino acid residue between positions 98 and 99.

25 If this is the case the subtilase investigated is a subtilase within the scope of the present invention.

The alignment performed in step i) above is performed as described above by using the GAP routine.

Based on this description it is routine for a person  
30 skilled in the art to identify the active site loop (b) in a subtilase and determine if the subtilase in question is within the scope of the invention. If a variant is constructed by site

directed mutagenesis, it is of course known beforehand if the subtilase variant is within the scope of the invention.

A subtilase variant of the invention may be constructed by standard techniques known in the art such as by site-directed/random mutagenesis or by DNA shuffling of different subtilase sequences. See section "PRODUCING A SUBTILASE VARIANT" and Material and methods herein (vide infra) for further details.

- In further embodiments the invention relates to
- 10 1. an isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is chosen from the group comprising: T, G, A, and S;
  2. an isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is chosen  
15 from the group of charged amino acid residues comprising: D, E, H, K, and R, more preferably D, E, K and R;
  3. an isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is chosen from the group of hydrophilic amino acid residues comprising:  
20 C, N, Q, S and T, more preferably N, Q, S and T;
  4. an isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is chosen from the group of small hydrophobic amino acid residues comprising: A, G and V; or
  - 25 5. an isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is chosen from the group of large hydrophilic amino acid residues comprising: F, I, L, M, P, W and Y, more preferably F, I, L, M, and Y.

In a further embodiment, the invention relates to an  
30 isolated subtilase enzyme according to the invention, wherein said insertion between positions 98 and 99 comprises at least



two amino acids, as compared to the corresponding active site loop in BLSAVI.

In further embodiments the invention relates to an isolated subtilase enzyme comprising at least one insertion, chosen from the group comprising (in BASBPN numbering):

X98X{T,G,A,S}

X98X{D,E,K,R}

X98X{H,V,C,N,Q}

10 X98X{F,I,L,M,P,W,Y}

or more specific for subtilisin 309 and closely related subtilases, such as BAALKP, BLSUBL, and BSKSMK

A98AA

15 A98AT

A98AG

A98AS

A98AD

20 A98AE

A98AK

A98AR

A98AH

25 A98AV

A98AC

A98AN

A98AQ

30 A98AF

A98AI

A98AL

A98AM

A98AP

A98AW

A98AY

5        Furthermore the invention relates to subtilases  
comprising the following multiple insertions in position 98

A98AGSGG

A98ATGSG

A98AGGGS

10 A98ASGSG

A98ATGTG

A98ASGTG

A98AGGGG

A98AGSGG

15

or any of the following combinations

A98ATD

A98ADT

G97D+A98AT

20 G97E+A98AT

G97K+A98AT

G97N+A98AT

G97Q+A98AT

G97R+A98AT

25 G97GD+A98AT

S87G+A98AGGGS

A98AT+S99SD

L96LD+A98AT

A98AT+Y167A

30 A98AT+R247K

A98GP+S99A

A98AS+A133E+T143K

A98AT+A108C+A138C

A98AT+Y167A+R170S+A194P

A98GI+S99H+G100S+S101A

s           It is well known in the art that a so-called conservative substitution of one amino acid residue to a similar amino acid residue is expected to produce only a minor change in the characteristic of the enzyme.

          Table III below list groups of conservative amino acid  
10 substitutions.

Table III

## Conservative amino acid substitutions

Common Property	Amino Acid
Basic (positive charge)	K = lysine
	H = histidine
Acidic (negative charge)	E = glutamic acid
	D = aspartic acid
Polar	Q = glutamine
	N = asparagine
Hydrophobic	L = leucine
	I = isoleucine
	V = valine
	M = methionine
Aromatic	F = phenylalanine
	W = tryptophan
Small	Y = tyrosine
	G = glycine
	A = alanine
	S = serine
	T = threonine

According to this principle subtilase variants comprising conservative substitutions, such as G97A+A98AS+S99G, 5 G97S+A98AT+S99A are expected to exhibit characteristics that are not drastically different from each other.

Based on the disclosed and/or exemplified subtilase variants herein, it is routine work for a person skilled in the art to identify suitable conservative modification(s) to these 10 variants in order to obtain other subtilase variants exhibiting similarly improved wash-performance.

According to the invention it the subtilases of the invention belong to the subgroups I-S1 and I-S2, especially

subgroup I-S2, both for isolating novel enzymes of the invention from nature or from the artificial creation of diversity, and for designing and producing variants from a parent subtilase.

In relation to variants from subgroup I-S1, it is preferred to choose a parent subtilase from the group comprising BSS168 (BSSAS, BSAPRJ, BSAPRN, BMSAMP), BASBPN, BSSDY, BLSCAR (BLKERA, BLSCA1, BLSCA2, BLSCA3), BSSPRC, and BSSPRD, or functional variants thereof having retained the characteristic of sub-group I-S1.

10 In relation to variants from subgroup I-S2 it is preferred to choose a parent subtilase from the group comprising BSAPRQ, BLS147 (BSAPRM, BAH101), BLSAVI (BSKSMK, BAALKP, BLSUBL), BYSYAB, and BSAPRS, or functional variants thereof having retained the characteristic of sub-group I-S2.

15 In particular said parent subtilase is BLSAVI (SAVINASE® NOVO NORDISK A/S), and a preferred subtilase variant of the invention is accordingly a variant of SAVINASE®.

The present invention also comprises any of the above mentioned subtilases of the invention in combination with any other modification to the amino acid sequence thereof. Especial-  
20 ly combinations with other modifications known in the art to provide improved properties to the enzyme are envisaged. The art describe a number of subtilase variants with different improved properties and a number of those are mentioned in the "Back-  
25 ground of the invention" section herein (*vide supra*). Those references are disclosed here as references to identify a subtilase variant, which advantageously can be combined with a subtilase variant of the invention.

Such combinations comprise the positions: 222 (improve  
30 oxidation stability), 218 (improves thermal stability), substitutions in the Ca-binding sites stabilizing the enzyme, e.g. position 76, and many other apparent from the prior art.

In further embodiments a subtilase variant of the invention may advantageously be combined with one or more modification(s) in any of the positions:

27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218,  
5 222, 224, 235 and 274.

Specifically the following BLSAVI, BLSUBL, BSKSMK, and BAALKP variants are considered appropriate for combination:

K27R, \*36D, S57P, N76D, S87N, G97N, S101G, S103A, V104A, V104I,  
V104N, V104Y, H120D, N123S, Y167, R170, Q206E, N218S, M222S,  
10 M222A, T224S, K235L and T274A.

Furthermore variants comprising any of the variants S101G+V104N, S87N+S101G+V104N, K27R+V104Y+N123S+T274A, N76D+S103A+V104I or N76D+V104A or other combinations of these mutations (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A)  
15 in combination with any one or more of the modification(s) mentioned above exhibit improved properties.

Even further subtilase variants of the main aspect(s) of the invention are preferably combined with one or more modification(s) in any of the positions 129, 131, 133 and 194, preferably  
20 bly as 129K, 131H, 133P, 133D and 194P modifications, and most preferably as P129K, P131H, A133P, A133D and A194P modifications. Any of those modification(s) are expected to provide a higher expression level of a subtilase variant of the invention in the production thereof.

25 Accordingly, an even further embodiment of the invention relates to a variant according to the invention, wherein said modification is chosen from the group comprising:

#### PRODUCING A SUBTILASE VARIANT

30 Many methods for cloning a subtilase of the invention and for introducing insertions into genes (e.g. subtilase genes) are

well known in the art, cf. the references cited in the  
"BACKGROUND OF THE INVENTION" section.

In general standard procedures for cloning of genes and  
introducing insertions (random and/or site directed) into said  
genes may be used in order to obtain a subtilase variant of the  
invention. For further description of suitable techniques refer-  
ence is made to Examples herein (*vide infra*) and (Sambrook et  
al. (1989) Molecular cloning: A laboratory manual, Cold Spring  
Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al.  
(eds.) "Current protocols in Molecular Biology". John Wiley and  
Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular  
Biological Methods for Bacillus". John Wiley and Sons, 1990);  
and WO 96/34946.

Further a subtilase variant of the invention may be  
constructed by standard techniques for artificial creation of  
diversity, such as by DNA shuffling of different subtilase genes  
(WO 95/22625; Stemmer WPC, Nature 370:389-91 (1994)). DNA  
shuffling of e.g. the gene encoding Savinase® with one or more  
partial subtilase sequences identified in nature to comprise an  
active site (b) loop regions longer than the active site (b)  
loop of Savinase®, will after subsequent screening for improved  
wash performance variants, provide subtilase variants according  
to the invention.

## 25 EXPRESSION VECTORS

A recombinant expression vector comprising a DNA  
construct encoding the enzyme of the invention may be any vector  
which may conveniently be subjected to recombinant DNA pro-  
cedures.

30 The choice of vector will often depend on the host cell  
into which it is to be introduced. Thus, the vector may be an  
autonomously replicating vector, i.e. a vector which exists as

an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one that on introduction into a host cell is integrated into the host cell genome in part or in its entirety and replicated together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the enzyme of the invention is operably linked to additional segments required for  
10 transcription of the DNA. In general, the expression vector is derived from plasmid or viral DNA, or may contain elements of both. The term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and  
15 proceeds through the DNA sequence coding for the enzyme.

The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

20 Examples of suitable promoters for use in bacterial host cells include the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* alpha-amylase gene, the *Bacillus subtilis* alkaline protease gene, or the *Bacillus*  
25 *pumilus* xylosidase gene, or the phage Lambda P<sub>R</sub> or P<sub>L</sub> promoters or the *E. coli* lac, trp or tac promoters.

The DNA sequence encoding the enzyme of the invention may also, if necessary, be operably connected to a suitable terminator.

30 The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.



The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, or a gene encoding resistance to e.g. antibiotics like kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycine, or the like, or resistance to heavy metals or herbicides.

To direct an enzyme of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the enzyme in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the enzyme. The secretory signal sequence may be that normally associated with the enzyme or may be from a gene encoding another secreted protein.

The procedures used to ligate the DNA sequences coding for the present enzyme, the promoter and optionally the terminator and/or secretory signal sequence, respectively, or to assemble these sequences by suitable PCR amplification schemes, and to insert them into suitable vectors containing the information necessary for replication or integration, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

25

#### HOST CELL

The DNA sequence encoding the present enzyme introduced into the host cell may be either homologous or heterologous to the host in question. If homologous to the host cell, i.e. produced by the host cell in nature, it will typically be operably connected to another promoter sequence or, if applicable, another secretory signal sequence and/or terminator sequence than in its

30

natural environment. The term "homologous" is intended to include a DNA sequence encoding an enzyme native to the host organism in question. The term "heterologous" is intended to include a DNA sequence not expressed by the host cell in nature. Thus, the DNA sequence may be from another organism, or it may be a synthetic sequence.

The host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell which is capable of producing the present enzyme and includes bacteria, yeast, fungi and higher eukaryotic cells including plants.

Examples of bacterial host cells which, on cultivation, are capable of producing the enzyme of the invention are gram-positive bacteria such as strains of *Bacillus*, such as strains of *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. megatherium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or gram-negative bacteria such as *E. coli*.

The transformation of the bacteria may be effected by protoplast transformation, electroporation, conjugation, or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

When expressing the enzyme in bacteria such as *E. coli*, the enzyme may be retained in the cytoplasm, typically as insoluble granules (known as inclusion bodies), or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed and the granules are recovered and denatured after which the enzyme is refolded by diluting the denaturing agent. In the latter case, the enzyme may be recovered from the periplasmic space by disrupting the cells,

e.g. by sonication or osmotic shock, to release the contents of the periplasmic space and recovering the enzyme.

When expressing the enzyme in gram-positive bacteria such as *Bacillus* or *Streptomyces* strains, the enzyme may be retained in the cytoplasm, or may be directed to the extracellular medium by a bacterial secretion sequence. In the latter case, the enzyme may be recovered from the medium as described below.

#### METHOD OF PRODUCING SUBTILASE

10       The present invention provides a method of producing an isolated enzyme according to the invention, wherein a suitable host cell, which has been transformed with a DNA sequence encoding the enzyme, is cultured under conditions permitting the production of the enzyme, and the resulting enzyme is recovered  
15 from the culture.

When an expression vector comprising a DNA sequence encoding the enzyme is transformed into a heterologous host cell it is possible to enable heterologous recombinant production of the enzyme of the invention.

20       Thereby it is possible to make a highly purified subtilase composition, characterized in being free from homologous impurities.

In this context homologous impurities means any impurities (e.g. other polypeptides than the enzyme of the  
25 invention) which originate from the homologous cell where the enzyme of the invention is originally obtained from.

The medium used to culture the transformed host cells may be any conventional medium suitable for growing the host cells in question. The expressed subtilase may conveniently be  
30 secreted into the culture medium and may be recovered therefrom by well-known procedures including separating the cells from the medium by centrifugation or filtration, precipitating

proteinaceous components of the medium by means of a salt such as ammonium sulfate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

5

#### USE OF A SUBTILASE VARIANT OF THE INVENTION

A subtilase protease variant of the invention may be used for a number of industrial applications, in particular within the detergent industry.

10 Further the invention relates to an enzyme composition, which comprise a subtilase variant of the invention.

An summary of preferred industrial applications and corresponding preferred enzyme compositions are described below.

This summary is not in any way intended to be a complete  
15 list of suitable applications of a subtilase variant of the invention. A subtilase variants of the invention may be used in other industrial applications known in the art to include use of a protease, in particular a subtilase.

#### 20 DETERGENT COMPOSITIONS COMPRISING THE MUTANT ENZYMES

The present invention comprises the use of the mutant enzymes of the invention in cleaning and detergent compositions and such compositions comprising the mutant subtilisin enzymes. Such cleaning and detergent compositions are well described in  
25 the art and reference is made to WO 96/34946; WO 97/07202; WO 95/30011 for further description of suitable cleaning and detergent compositions.

Furthermore the example(s) below demonstrate the improvements in wash performance for a number of subtilase  
30 variants of the invention.

#### Detergent Compositions

The enzyme of the invention may be added to and thus become a component of a detergent composition.

The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

10 In a specific aspect, the invention provides a detergent additive comprising the enzyme of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a man-  
15 nanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredi-  
20 ents, etc.), and the enzyme(s) should be present in effective amounts.

Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. The  
25 protease may be a serine protease or a metallo protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus*, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and  
30 subtilisin 168 (described in WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin)

and the *Fusarium* protease described in WO 89/06270 and WO 94/25583.

Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.

Preferred commercially available protease enzymes include Alcalase™, Savinase™, Primase™, Duralase™, Esperase™, and 10 Kannase™ (Novo Nordisk A/S), Maxatase™, Maxacal™, Maxapem™, Properase™, Purafect™, Purafect OxP™, FN2™, and FN3™ (Genencor International Inc.).

Lipases: Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are 15 included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), e.g. from *H. lanuginosa* (*T. lanuginosus*) as described in EP 258 068 and EP 305 216 or from *H. insolens* as described in WO 96/13580, a *Pseudomonas* lipase, e.g. from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218 272), 20 *P. cepacia* (EP 331 376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, e.g. from *B. subtilis* (Dartois et al. (1993), *Biochemica et Biophysica Acta*, 1131, 253-360), *B. stearothermophilus* (JP 25 64/744992) or *B. pumilus* (WO 91/16422).

Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202.

30 Preferred commercially available lipase enzymes include Lipolase™ and Lipolase Ultra™ (Novo Nordisk A/S).

Amylases: Suitable amylases ( $\alpha$  and/or  $\beta$ ) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example,  $\alpha$ -amylases obtained from *Bacillus*, e.g. a special strain of *B. licheniformis*, described in more detail in GB 1,296,839.

Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 10 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.

Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™ and BAN™ (Novo Nordisk A/S), Rapidase™ and Purastar™ (from Genencor International Inc.).

15 Cellulases: Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola* 20 *insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 25 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT/DK98/00299.

30 Commercially available cellulases include Celluzyme™, and Carezyme™ (Novo Nordisk A/S), Clazinase™, and Puradax HA™

(Genencor International Inc.), and KAC-500(B)<sup>TM</sup> (Kao Corporation).

Peroxidases/Oxidases: Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.

Commercially available peroxidases include Guardzyme<sup>TM</sup> (Novo Nordisk A/S).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or



sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (''glucamides'').

The detergent may contain 0-65 % of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, 5 maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a  $H_2O_2$  source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as 10 tetraacetylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, 15 e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and 20 WO 92/19708.

The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, 25 bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

It is at present contemplated that in the detergent compositions any enzyme, in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-100 mg of enzyme 30 protein per liter of wash liquor, preferably 0.05-5 mg of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202 which is hereby incorporated as reference.

#### 5 LEATHER INDUSTRY APPLICATIONS

A subtilase of the invention may be used in the leather industry, in particular for use in depilation of skins.

In said application a subtilase variant of the invention is preferably used in an enzyme composition which further  
10 comprises another protease.

For a more detailed description of suitable other proteases see section relating to suitable enzymes for use in a detergent composition (*vide supra*).

#### 15 WOOL INDUSTRY APPLICATIONS

A subtilase of the invention may be used in the wool industry, in particular for use in cleaning of clothes comprising wool.

In said application a subtilase variant of the invention  
20 is preferably used in an enzyme composition which further comprises another protease.

For a more detailed description of suitable other proteases see section relating to suitable enzymes for use in a detergent composition (*vide supra*).

25 The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention as claimed.

#### MATERIALS AND METHODS

30

##### STRAINS:

*B. subtilis* DN1885 (Diderichsen et al., 1990).

*B. lentus* 309 and 147 are specific strains of *Bacillus lentus*, deposited with the NCIB and accorded the accession numbers NCIB 10309 and 10147, and described in US Patent No. 3,723,250 incorporated by reference herein.

5 *E. coli* MC 1000 (M.J. Casadaban and S.N. Cohen (1980); *J. Mol. Biol.* 138 179-207), was made  $r^-$ ,  $m^+$  by conventional methods and is also described in US Patent Application Serial No. 039,298.

10

#### PLASMIDS:

pJS3: *E. coli* - *B. subtilis* shuttle vector containing a synthetic gene encoding for subtilase 309. (Described by Jacob Schiødt et al. in *Protein and Peptide letters* 3:39-44 (1996)).

15 pSX222: *B. subtilis* expression vector (Described in WO 96/34946).

#### GENERAL MOLECULAR BIOLOGY METHODS:

Unless otherwise mentioned the DNA manipulations and  
20 transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) *Molecular cloning: A laboratory manual*, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) *"Current protocols in Molecular Biology"*. John Wiley and Sons, 1995; Harwood, C. R., and  
25 Cutting, S. M. (eds.) *"Molecular Biological Methods for Bacillus"*. John Wiley and Sons, 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers.

#### 30 ENZYMES FOR DNA MANIPULATIONS

Unless otherwise mentioned all enzymes for DNA manipulations, such as e.g. restriction endonucleases, ligases etc., are

obtained from New England Biolabs, Inc.

#### PROTEOLYTIC ACTIVITY

In the context of this invention proteolytic activity is expressed in Kilo NOVO Protease Units (KNPU). The activity is determined relatively to an enzyme standard (SAVINASE<sup>®</sup>), and the determination is based on the digestion of a dimethyl casein (DMC) solution by the proteolytic enzyme at standard conditions, i.e. 50°C, pH 8.3, 9 min. reaction time, 3 min. measuring time. A folder AF 220/1 is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

A GU is a Glycine Unit, defined as the proteolytic enzyme activity which, under standard conditions, during a 15 minutes' incubation at 40°C, with N-acetyl casein as substrate, produces an amount of NH<sub>2</sub>-group equivalent to 1 mmole of glycine.

Enzyme activity can also be measured using the PNA assay, according to reaction with the soluble substrate succinyl-alanine-alanine-proline-phenyl-alanine-para-nitro-phenol, which is described in the Journal of American Oil Chemists Society, Rothgeb, T.M., Goodlander, B.D., Garrison, P.H., and Smith, L.A., (1988).

#### FERMENTATION:

Fermentations for the production of subtilase enzymes were performed at 30°C on a rotary shaking table (300 r.p.m.) in 500 ml baffled Erlenmeyer flasks containing 100 ml BPX medium for 5 days.

Consequently in order to make an e.g. 2 liter broth 20 Erlenmeyer flasks were fermented simultaneously.

30

#### MEDIA:

BPX Medium Composition (per liter)

Potato starch	100 g
Ground barley	50 g
Soybean flour	20 g
Na <sub>2</sub> HPO <sub>4</sub> × 12 H <sub>2</sub> O	9 g
Pluronic	0.1 g
Sodium caseinate	10 g

The starch in the medium is liquefied with  $\alpha$ -amylase and the medium is sterilized by heating at 120°C for 45 minutes. After sterilization the pH of the medium is adjusted to 9 by addition of NaHCO<sub>3</sub> to 0.1 M.

#### EXAMPLE 1

##### CONSTRUCTION AND EXPRESSION OF ENZYME VARIANTS:

##### SITE-DIRECTED MUTAGENESIS:

10 Subtilase 309 site-directed variants of the invention comprising specific insertions in the active site loop (b) between positions 98 and 99 were made by traditional cloning of DNA fragments (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989) produced by PCR of  
15 oligos containing the desired insertions (see below).

The template plasmid DNA was pJS3, or an analogue of this containing a variant of Subtilase 309.

Insertions were introduced by oligo directed mutagenesis to the construction of A98AX insertion variants (X = any amino  
20 acid residue inserted between positions 98 and 99) resulting in A98AX subtilase 309 variants.

The Subtilase 309 variants were transformed into *E. coli*. DNA purified from a over night culture of these transformants were transformed into *B. subtilis* by  
25 restriction endonuclease digestion, purification of DNA fragments, ligation, transformation of *B. subtilis*.

Transformation of *B. subtilis* was performed as described by Dubnau et al., 1971, *J. Mol. Biol.* 56, pp. 209-221.

LOCALIZED RANDOM MUTAGENESIS IN ORDER TO INSERT RANDOM  
5 INSERTIONS IN A LOCALIZED REGION:

The overall strategy used to perform localized random mutagenesis was:

A mutagenic primer (oligonucleotide) was synthesized, that corresponds to the DNA sequence flanking the site of  
10 insertion, separated by the DNA base pairs defining the insertion.

Subsequently, the resulting mutagenic primer was used in a PCR reaction with a suitable opposite primer. The resulting PCR fragment was purified and extended in a second PCR-reaction,  
15 before being digested by endonucleases and cloned into the *E. coli* - *B. subtilis* shuttle vector (see below).

Alternatively, and if necessary, the resulting PCR fragment is used in a second PCR reaction as a primer with a second suitable opposite primer to allow digestion and cloning  
20 of the mutagenized region into the shuttle vector. The PCR reactions are performed under normal conditions.

Following this strategy a localized random library was constructed in SAVINASE wherein insertions were introduced in the active site loop region between positions 98 and 99.

25 The mutations were introduced by mutagenic primers (see below), so that all 20 amino acids are represented (N = 25% of A, T, C, and G; whereas S = 50% C and G. The produced PCR fragment was extended towards the N-terminal of Savinase by another round of PCR by combination of a overlapping sequence  
30 with a PCR-fragment produced by PCR-amplification with primers; 5' CTA AAT ATT CGT GGTGGC GC 3' (*sense*) and 5' GAC TTT AAC AGC GTA TAG CTC AGC 3' (*antisense*). The extended DNA-fragments were

cloned into the Hind III- and Mlu I- sites of the modified plasmid pJS3 (see above), and ten randomly chosen *E. coli* colonies were sequenced to confirm the mutations designed.

The mutagenic primer (5' GCT GAG CTA TAC GCT GTT AAA GTC  
5 CTA GGG GCG NNS AGC GGT TCA GGT TCG GTC AGC 3' (sense)) was used in a PCR reaction with a suitable anti-sense opposite primer, situated downstream of the Mlu I site in pJS3 (e.g. 5'- CCC TTT AAC CGC ACA GCG TTT -3' (anti-sense)) and the plasmid pJS3 as template. This resulting PCR product was cloned into the pJS3  
10 shuttle vector by using the restriction enzymes Hind III and Mlu I.

The random library was transformed into *E. coli* by well known techniques.

The library prepared contained approximately 100,000  
15 individual clones/library.

Ten randomly chosen colonies were sequenced to confirm the mutations designed.

In order to purify a subtilase variant of the invention, the *B. subtilis* pJS3 expression plasmid comprising a variant of  
20 the invention was transformed into a competent *B. subtilis* strain and was fermented as described above in a medium containing 10 µg/ml Chloramphenicol (CAM).

## EXAMPLE 2

### 25 PURIFICATION OF ENZYME VARIANTS:

This procedure relates to purification of a 2 liter scale fermentation for the production of the subtilases of the invention in a *Bacillus* host cell.

Approximately 1.6 liters of fermentation broth were  
30 centrifuged at 5000 rpm for 35 minutes in 1 liter beakers. The supernatants were adjusted to pH 6.5 using 10% acetic acid and filtered on Seitz Supra S100 filter plates.



The filtrates were concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate was centrifuged and filtered prior to absorption at room temperature on a Bacitracin affinity column at pH 7. The protease was eluted from the Bacitracin column at room temperature using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.

The fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equilibrated with a buffer containing 0.01 dimethylglutaric acid, 0.2 M boric acid and 0.002 m calcium chloride adjusted to pH 6.5.

Fractions with proteolytic activity from the Sephadex G25 column were combined and applied to a 150 ml CM Sepharose CL 6B cation exchange column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid, and 0.002 M calcium chloride adjusted to pH 6.5.

The protease was eluted using a linear gradient of 0-0.1 M sodium chloride in 2 litres of the same buffer (0-0.2 M sodium chloride in case of Subtilisin 147).

In a final purification step protease containing fractions from the CM Sepharose column were combined and concentrated in an Amicon ultrafiltration cell equipped with a GR81PP membrane (from the Danish Sugar Factories Inc.).

By using the techniques of Example 1 for the construction and fermentation, and the above isolation procedure the following subtilisin 309 variants were produced and isolated:

A98AT

A98AS

A98AD

A98AE

A98AP  
A98AG  
A98AH  
A98AI  
A98AT+Y167A  
A98AD  
A98AG  
A98AH  
A98AI  
A98AN  
A98AP  
A98AS  
A98AT  
A98AV  
A98AY  
A98SD  
A98TP  
A98TW  
A98ASGTG  
A98ATGSG  
A98ATGTG  
A98AGGGG  
A98AGSGG  
A98AT+Y167A  
A98AT+R247K  
A98GP+S99A  
G97D+A98AT  
G97E+A98AT  
G97K+A98AT  
G97N+A98AT  
G97Q+A98AT  
G97R+A98AT  
S87G+A98AGGS  
A98AS+A133E+T143K  
A98AT+A108C+A138C  
A98AT+Y167A+R170S+A194P  
A98GI+S99H+G100S+S101A

These variants were found to exhibit better wash performance than Savinase in a preliminary assay.

### 5 EXAMPLE 3

#### WASH PERFORMANCE OF DETERGENT COMPOSITIONS COMPRISING ENZYME VARIANTS

The following examples provide results from a number of washing tests that were conducted under the conditions indicated

MINI WASH

## WASH CONDITIONS:

	Europe	US
Detergent Dosage	4g/l	1g/l
Wash Temp	30°C	25°C
Wash Time	30min	10min
Water hardness	18°dH ( $\text{Ca}^{2+}/\text{Mg}^{2+} = 5:1$ )	6°dH ( $\text{Ca}^{2+}/\text{Mg}^{2+} = 2:1$ )
Ph	Not adjusted	Not adjusted
Enzyme conc.	1, 2, 5, 10, 30 nM	1, 2, 5, 10, 30 nM
Test system	150 ml glass beakers with a stirring rod	150 ml glass beakers with a stirring rod
Textile/volume	5 textile pieces (Ø 2.5 cm) in 50 ml detergent	5 textile pieces (Ø 2.5 cm) in 50 ml detergent
Test Material	EMPA116	EMPA117

## 5 DETERGENTS:

The detergents used were obtained from supermarkets in Denmark (OMO, datasheet ED-9745105) and the USA (Wisk, datasheet ED-9711893), respectively. Prior to use all enzymatic activity in the detergents was inactivated by micro wave treatment.

10

## SWATCHES;

The swatches used were EMPA116 and EMPA117, obtained from EMPA Testmaterialen, Movenstrasse 12, CH-9015 St. Gall, Switzerland.

15

## REFLECTANCE

Measurement of reflectance (R) on the test material was done at 460 nm using a Macbeth ColorEye 7000 photometer. The measurements were done according to the manufacturers protocol.

## 5 EVALUATION

The evaluation of the wash performance of a subtilase is determined by either the improvement factor or the performance factor for the subtilase investigated.

The improvement factor,  $IF_{\text{Dose/response}}$ , is defined as  
 10 the ratio between the slopes of the wash performance curves for a detergent containing the subtilase investigated and the same detergent containing a reference subtilase at the asymptotic concentration of the subtilase goes to zero

$$15 \quad IF_{\text{Dose/response}} = a/a_{\text{ref}}$$

The wash performance is calculated according to the formula I:

$$R = R_0 + \frac{a \cdot \Delta R_{\text{max}} \cdot c}{\Delta R_{\text{max}} + a \cdot c} \quad (I);$$

20 where

R is the wash performance in reflectance units;  $R_0$  is the intercept of the fitted curve with y-axis (blind); a is the slope of the fitted curve as  $c \rightarrow 0$ ; c is the enzyme concentration; and  $\Delta R_{\text{max}}$  is the theoretical maximal wash effect

25 as  $c \rightarrow \infty$ .

The performance factor, P, is calculated according to the formula II

$$P = \frac{R_{\text{Variant}} - R_{\text{Blank}}}{R_{\text{Savinase}} - R_{\text{Blank}}} \quad (II)$$

30 where

$R_{\text{variant}}$  is the reflectance of test material washed with 10nM variant;  $R_{\text{savinase}}$  is the reflectance of test material washed with 10nM Savinase;  $R_{\text{blank}}$  is the reflectance of test material washed with no enzyme

US (detergent: US Wisk, Swatch: EMPA117)

Variant	IFDose/response	P
A98AT	>3	2.3
A98AD		1.2
A98AG		1.1
A98AH		1.4
A98AI		1.2
A98AN		1.0
A98AP		1.3
A98AS		1.6
A98AV		1.1
A98AY		1.1
A98SD		1.2
A98TP		1.5
A98TW		1.2
A98AGGGG		1.1
A98ASGTG		1.1
A98ATGSG		1.3
A98ATGTG		1.2
A98AGSGG	----	1.7
A98AT+Y167A		1.7
A98AT+R247K		1.3
A98GP+S99A		1.1
G97D+A98AT		1.4
G97E+A98AT		1.6
G97K+A98AT		1.0
G97N+A98AT		1.2
G97Q+A98AT		1.0
G97R+A98AT		1.0
S87G+A98AGGGS		1.2
A98AS+A133E+T143K		0.8

Variant	IFDose/response	P
A98AT+A108C+A138C		1.2
A98AT+Y167A+R170S+A194P		1.3
A98GI+S99H+G100S+S101A		1.0

The subtilases of the inventions are thus seen to exhibit improved wash performance in comparison to Savinase<sup>®</sup>.

## PATENT CLAIMS

1. A Subtilase enzymes of the I-S1 and I-S2 sub-groups having at least one additional amino acid residue in position 98 of the active site loop (b) region from position 95 to 103, whereby said additional amino acid residue(s) correspond to the insertion of at least one amino acid residue between positions 98 and 99.
2. The isolated subtilase enzyme of claim 1, wherein said subtilase enzyme is a constructed variant having at least one inserted amino acid residue between positions 98 and 99 of a precursor subtilase.
3. The isolated subtilase enzyme of claim 1 or 2 selected from the group comprising
- X98X{A,T,G,S},  
X98X{D,E,K,R},  
X98X{H,V,C,N,Q}, and  
X98X{F,I,L,M,P,W,Y}
4. The isolated subtilase enzyme of claim 3, wherein said at least one additional or inserted amino acid residue is chosen from the group comprising: T, G, A, and S.
5. The isolated subtilase enzyme of claim 3, wherein said at least one additional or inserted amino acid residue is chosen from the group of charged amino acid residues comprising: D,E,H,K, and R, more preferably D,E,K and R.
6. The isolated subtilase enzyme of claim 3, wherein said at least one additional or inserted amino acid residue is chosen



from the group of hydrophilic amino acid residues comprising: C,N,Q,S and T, more preferably N,Q,S and T.

7. The isolated subtilase enzyme of claim 3, wherein said at least one additional or inserted amino acid residue is chosen from the group of small hydrophobic amino acid residues comprising: A,G and V.

8. The isolated subtilase enzyme of claim 3, wherein said at least one additional or inserted amino acid residue is chosen from the group of large hydrophobic amino acid residues comprising: F,I,L,M,P,W and Y, more preferably F,I,L,M, and Y.

9. The isolated subtilase enzyme according to any of the preceding claims, wherein said at least one additional or inserted amino acid residue, comprises more than one additional or inserted amino acid residue in the active site loop (b).

10. The subtilase variant of any of the preceding claims, wherein said insertion(s) between positions 98 and 99 are combined with one or more further modification(s) in any other position(s).

11. The subtilase variant of claim 15, wherein said further modification(s) are in one or more of the positions 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218, 222, 224, 235 and 274.

12. The subtilase variant of any of the preceding claims, wherein said modification(s) is/are combined with modification(s) in one or more of the positions 129, 131, 133 and 194.

13. The subtilase of any of the preceding claims, wherein the subtilase, or if the subtilase is a variant the parent subtilase, belongs to the sub-group I-S1.
- 5 14. The subtilase of claim 13, wherein the parent subtilase is chosen from the group comprising ABSS168, BASBPN, BSSDY, and BLSCAR, or functional variants thereof having retained the characteristic of sub-group I-S1.
- 10 15. The subtilase according to any of claims 1-14, wherein the subtilase, or if the subtilase is a variant, the parent subtilase belongs to the sub-group I-S2.
16. The subtilase of claim 15, wherein the parent subtilase is  
15 chosen from the group comprising BLS147, BLS309, BAPB92, TVTHER and BYSYAB, or functional variants thereof having retained the characteristic of sub-group I-S2.
17. The isolated subtilase enzyme of claim 3, 15 or 16 selected  
20 from the group comprising
- A98AA,
  - A98AT,
  - A98AG,
  - A98AS,

25 A98AD,

  - A98AE,
  - A98AK,
  - A98AR,
  - A98AH,

30 A98AV,

  - A98AC,
  - A98AN,

A98AQ,  
A98AF,  
A98AI,  
A98AL,  
5 A98AM,  
A98AP,  
A98AW,  
A98AY,  
A98SD,  
10 A98TP, and  
A98TW.

18. The subtilase variant of any of the claims 15 to 17, wherein said further modification(s) are chosen from the group  
15 comprising K27R, \*36D, S57P, N76D, S87N, G97N, S101G, V104A, V104N, V104Y, H120D, N123S, Y167X, R170X, Q206E, N218S, M222S, M222A, T224S, K235L, and T274A.

19. The subtilase variant of any of the claims 15 to 17, wherein  
20 said further modification(s) are chosen from the group comprising S101G+V104N, S87N+S101G+V104N, K27R+V104Y+N123S+T274A, N76D+S103A+V104I or N76D+V104A, or other combinations of these mutations (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A), in combination with any one or more  
25 of the substitutions, deletions and/or insertions mentioned in any of claims 1 to 14.

20. The subtilase variant of any of the claims 15 to 17, wherein said further modification(s) are chosen from the group further  
30 comprising P129K, P131H, A133P, A133D and A194P.

21. The variant according to any of the preceding claims comprising the modification chosen from the group comprising:

A98AT+Y167A; A98AT+S99SD; A98ATD; A98ADT A98AGSGG;  
A98ATGSG; A98AGGGS; A98AGGGG; A98ASGTG; A98ATGTG;  
5 S87G+A98AGGGS; L96LD+ A98AT; G97D+A98AT; G97E+A98AT;  
G97K+A98AT; G97N+A98AT; G97Q+A98AT; G97R+A98AT;  
G97GD+A98AT; A98AT+Y167A; A98AT+R247K; A98GP+S99A;  
A98AS+A133E+T143K; A98AT+A108C+A138C;  
A98AT+Y167A+R170S+A194P; A98GI+S99H+G100S+S101A.

10

22. A subtilase belonging to the I-S1 sub-group having the amino acid sequence:

1	10	20	30
A-Q-T-V-P-Y-G-I-P-L-I-K-A-D-K-V-Q-A-Q-G-F-K-G-A-N-V-K-V-A-V			
15	40	50	60
L-D-T-G-I-Q-A-S-H-P-D-L-N-V-V-G-G-A-S-F-V-A-G-E-A*-Y-N-T-D			
	70	80	90
G-N-G-H-G-T-H-V-A-G-T-V-A-A-L-D-N-T-T-G-V-L-G-V-A-P-S-V-S-L			
	98a	110	120
20	Y-A-V-K-V-L-N-S-X-S-G-S-G-T-Y-S-G-I-V-S-G-I-E-W-A-T-T-N-G-M-D		
	130	140	150
V-I-N-M-S-L-G-G-P-S-G-S-T-A-M-K-Q-A-V-D-N-A-Y-A-R-G-V-V-V-V			
	160	170	180
A-A-A-G-N-S-G-S-S-G-N-T-N-T-I-G-Y-P-A-K-Y-D-S-V-I-A-V-G-A-V			
25	190	200	210
D-S-N-S-N-R-A-S-F-S-S-V-G-A-E-L-E-V-M-A-P-G-A-G-V-Y-S-T-Y-P			
	220	230	240
T-S-T-Y-A-T-L-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N			
	250	260	270
30	L-S-A-S-Q-V-R-N-R-L-S-S-T-A-T-Y-L-G-S-S-F-Y-Y-G-K-G-L-I-N-V		
	275		
E-A-A-A-Q			

or a homologous subtilase having an amino acid sequence comprising a position 98a amino acid residue and exhibiting an identity of more than 70%, 75%, 80%, 85%, 90%, or 95% therewith.

5 23. A subtilase belonging to the I-S2 sub-group having the amino acid sequence:

.1	10	20	30
.A-Q-S-V-P-W-G-I-S-R-V-Q-A-P-A-A-H-N-R-G-L-T-G-S-G-V-K-V-A-V-			
.	40	50	60
10	.L-D-T-G-I-*S-T-H-P-D-L-N-I-R-G-G-A-S-F-V-P-G-E-P-*S-T-Q-D-		
.	70	80	90
.G-N-G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-E-L-			
.	98a	110	120
.Y-A-V-K-V-L-G-A-X-S-G-S-G-S-V-S-S-I-A-Q-G-L-E-W-A-G-N-N-G-M-H-			
15	130	140	150
.V-A-N-L-S-L-G-S-P-S-P-S-A-T-L-E-Q-A-V-N-S-A-T-S-R-G-V-L-V-V-			
.	160	170	180
.A-A-S-G-N-S-G-A-*G-S-I-S-*--*Y-P-A-R-Y-A-N-A-M-A-V-G-A-T-			
.	190	200	210
20	.D-Q-N-N-N-R-A-S-F-S-Q-Y-G-A-G-L-D-I-V-A-P-G-V-N-V-Q-S-T-Y-P-		
.	220	230	240
.G-S-T-Y-A-S-L-N-G-T-S-M-A-T-P-H-V-A-G-A-A-A-L-V-K-Q-K-N-P-S-			
.	250	260	270
.W-S-N-V-Q-I-R-N-H-L-K-N-T-A-T-S-L-G-S-T-N-L-Y-G-S-G-L-V-N-A-			
25	275		
.E-A-A-T-R			

or a homologous subtilase having an amino acid sequence comprising a position 98a amino acid residue and exhibiting an identity of more than 70%, 75%, 80%, 85%, 90%, or 95% therewith.

24. The subtilase variant of claims 22 or 23, wherein X in position 98a is chosen from the group comprising T, A, G, S, and P.

5

25. An isolated DNA sequence encoding a subtilase or a subtilase variant of any of the claims 1 to 24.

26. An expression vector comprising an isolated DNA sequence of  
10 claim 25.

27. A microbial host cell transformed with an expression vector of claim 26.

15 28. The microbial host of claim 27, which is a bacterium, preferably a *Bacillus*, especially *B. lentus*.

29. The microbial host of claim 27, which is a fungus or yeast, preferably a filamentous fungus, especially an *Aspergillus*.

20

30. A method for producing a subtilase or a subtilase variant of any of claims 1 to 24, wherein a host of any of claims 27 to 29 is cultured under conditions conducive to the expression and secretion of said variant, and the variant is recovered.

25

31. A composition comprising a subtilase or a subtilase variant according to any of claims 1 to 24.

32. The composition according to claim 31, which additionally  
30 comprises a cellulase, lipase, cutinase, oxidoreductase, another protease, or an amylase.

33. The composition according to claim 31 or 32, wherein the composition is a detergent composition.

34. Use of a subtilase or a subtilase variant according to any of  
s claims 1 to 24 or an enzyme composition according to claims 31  
or 32 in a laundry and/or a dishwash detergent.

1/5

No:	1	10	20	30	40	50
a)	AQSVPYGVSQIKAPALHSQGYTGSNVKVAVIDSGIDSSHPDLKVAGGASM					
b)	AQSVPWGISRVQAPAAHNRGLTGSVKVAVLDTGI*STHPDLNIRGGASF					

No:	60	70	80	90	100
a)	VPSETNPFQDNNSHGTHVAGTVAALNNSIGVLGVAPSASLYAVKVLGADG				
b)	VPGEPT*QDGNHGTHVAGTIAALNNSIGVLGVAPSAELYAVKVLGASG				

No:	110	120	130	140	150
a)	SGQYSWIINGIEWAIANNMDVINMSLGGPSGSAALKAASVDKAVASGVVVV				
b)	SGSVSSIAQGLEWAGNNGMHVANLSLGSPPSATLEQAVNSATSRGVLVV				

No:	160	170	180	190	200
a)	AAAGNEGTSGSSSTVGYPGKYPSVIAVGAVDSSNQRFSSVGPGLDVM				
b)	AASGNSG*AGS***ISYPARYANAMAVGATDQNNNRASFQYAGLDIVA				

No:	210	220	230	240	250
a)	PGVSIQSTLPGNKYGAYNGTSMASPHVAGAAALILSKHPNWTNTQVRSSL				
b)	PGVNVQSTYPGSTYASLNGTSMATPHVAGAAALVKQKNPSWSNVQIRNHL				

No:	260	270	275
a)	ENTTTKLGDsfyygkGLINVQAAQ		
b)	KNTATSLGSTNLYGSGLVNAEAATR		

Fig.1



2/5

No: 1 10 20 30  
a) A-Q-S-V-P-Y-G-V-S-Q-I-K-A-P-A-L-H-S-Q-G-Y-T-G-S-N-V-K-V-A-V-  
b) A-Q-S-V-P-W-G-I-S-R-V-Q-A-P-A-A-H-N-R-G-L-T-G-S-G-V-K-V-A-V-

No: 40 50 60  
a) I-D-S-G-I-D-S-S-H-P-D-L-K-V-A-G-G-A-S-M-V-P-S-E-T-N-P-F-Q-D-  
b) L-D-T-G-I-\*S-T-H-P-D-L-N-I-R-G-G-A-S-F-V-P-G-E-P-\*S-T-Q-D-

No: 70 80 90  
a) N-N-S-H-G-T-H-V-A-G-T-V-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-S-L-  
b) G-N-G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-E-L-

No: 100 110 120  
a) Y-A-V-K-V-L-G-A-D-G-S-G-Q-Y-S-W-I-I-N-G-I-E-W-A-I-A-N-N-M-D-  
b) Y-A-V-K-V-L-G-A-S-G-S-G-S-V-S-S-I-A-Q-G-L-E-W-A-G-N-N-G-M-H-

No: 130 140 150  
a) V-I-N-M-S-L-G-G-P-S-G-S-A-A-L-K-A-A-V-D-K-A-V-A-S-G-V-V-V-V-  
b) V-A-N-L-S-L-G-S-P-S-P-S-A-T-L-E-Q-A-V-N-S-A-T-S-R-G-V-L-V-V-

No: 160 170 180  
a) A-A-A-G-N-E-G-T-S-G-S-S-S-T-V-G-Y-P-G-K-Y-P-S-V-I-A-V-G-A-V-  
b) A-A-S-G-N-S-G-A-\*G-S-I-S-\*-\*Y-P-A-R-Y-A-N-A-M-A-V-G-A-T-

No: 190 200 210  
a) D-S-S-N-Q-R-A-S-F-S-S-V-G-P-E-L-D-V-M-A-P-G-V-S-I-Q-S-T-L-P-  
b) D-Q-N-N-N-R-A-S-F-S-Q-Y-G-A-G-L-D-I-V-A-P-G-V-N-V-Q-S-T-Y-P-

No: 220 230 240  
a) G-N-K-Y-G-A-Y-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N-  
b) G-S-T-Y-A-S-L-N-G-T-S-M-A-T-P-H-V-A-G-A-A-A-L-V-K-Q-K-N-P-S-

No: 250 260 270  
a) W-T-N-T-Q-V-R-S-S-L-E-N-T-T-T-K-L-G-D-S-F-Y-Y-G-K-G-L-I-N-V-  
b) W-S-N-V-Q-I-R-N-H-L-K-N-T-A-T-S-L-G-S-T-N-L-Y-G-S-G-L-V-N-A-

No: 275  
a) Q-A-A-A-Q  
b) E-A-A-T-R

Fig.1a

3/5

No.:           10           20           30           40           50  
a) AQSVPYGVVSQIKAPALHSQGYTGSNVKVAVIDSGIDSSHPLDKVAGGASM  
g) AQTVPYGIPLIKADKVQAQGFKGANVKVAVLDTGIQASHPDLNVVGGASF

No.:           60           70           80           90           100  
a) VPSETNPFQDNNSHGTHVAGTVAALNNSIGVLGVAPSASLYAVKVLGADG  
g) VAGEAYN\*TDGNHGHGTHVAGTVAALDNTTGVLGVAPSVSLYAVKVLNSSG

No.:           110           120           130           140           150  
a) SGQYSWIINGIEWAIANNMDVINMSLGGPSGSAALKAAVDKAVASGVVVV  
b) SGTYSGIVSGIEWATTNGMDVINMSLGGPSGSTAMKQAVDNAYARGVVVV

No.:           160           170           180           190           200  
a) AAAGNEGTSGSSSTVGYPGKYPSVIAVGAVDSSNQRAFSSVGPGLDVMA  
b) AAAGNSGSSGNTNTIGYPAKYDSVIAVGAVDSNSNRASFSSVGAELEVMA

No.:           210           220           230           240           250  
a) PGVSIQSTLPGNKYGAYNGTSMASPHVAGAAALILSKHPNWTNTQVRSSL  
b) PGAGVYSTYPTSTYATLNGTSMASPHVAGAAALILSKHPNLSASQVRNRL

No.:           260           270           275  
a) ENTTTKLGDSFYYGKGLINVQAAAQ  
b) SSTATYLGSSFYYGKGLINVEAAAQ

Fig. 2

4/5

No: 1 10 20 30  
a) A-Q-S-V-P-Y-G-V-S-Q-I-K-A-P-A-L-H-S-Q-G-Y-T-G-S-N-V-K-V-A-V-  
g) A-Q-T-V-P-Y-G-I-P-L-I-K-A-D-K-V-Q-A-Q-G-F-K-G-A-N-V-K-V-A-V-

No: 40 50 60  
a) I-D-S-G-I-D-S-S-H-P-D-L-K-V-A-G-G-A-S-M-V-P-S-E-T-N-P-F-Q-D-  
g) L-D-T-G-I-Q-A-S-H-P-D-L-N-V-V-G-G-A-S-F-V-A-G-E-A\*-Y-N-T-D-

No: 70 80 90  
a) H-G-T-H-V-N-N-S-A-G-T-V-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-S-L-  
g) G-N-G-H-G-T-H-V-A-G-T-V-A-A-L-D-N-T-T-G-V-L-G-V-A-P-S-V-S-L-

No: 100 110 120  
a) Y-A-V-K-V-L-G-A-D-G-S-G-Q-Y-S-W-I-I-N-G-I-E-W-A-I-A-N-N-M-D-  
g) Y-A-V-K-V-L-N-S-S-G-S-G-T-Y-S-G-I-V-S-G-I-E-W-A-T-T-N-G-M-D-

No: 130 140 150  
a) V-I-N-M-S-L-G-G-P-S-G-S-A-A-L-K-A-A-V-D-K-A-V-A-S-G-V-V-V-V-  
g) V-I-N-M-S-L-G-G-P-S-G-S-T-A-M-K-Q-A-V-D-N-A-Y-A-R-G-V-V-V-V-

No: 160 170 180  
a) A-A-A-G-N-E-G-T-S-G-S-S-S-T-V-G-Y-P-G-K-Y-P-S-V-I-A-V-G-A-V-  
g) A-A-A-G-N-S-G-S-S-G-N-T-N-T-I-G-Y-P-A-K-Y-D-S-V-I-A-V-G-A-V-

No: 190 200 210  
a) D-S-S-N-Q-R-A-S-F-S-S-V-G-P-E-L-D-V-M-A-P-G-V-S-I-Q-S-T-L-P-  
g) D-S-N-S-N-R-A-S-F-S-S-V-G-A-E-L-E-V-M-A-P-G-A-G-V-Y-S-T-Y-P-

No: 220 230 240  
a) G-N-K-Y-G-A-Y-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N-  
g) T-S-T-Y-A-T-L-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N-

No: 250 260 270  
a) W-T-N-T-Q-V-R-S-S-L-E-N-T-T-T-K-L-G-D-S-F-Y-Y-G-K-G-L-I-N-V-  
g) L-S-A-S-Q-V-R-N-R-L-S-S-T-A-T-Y-L-G-S-S-F-Y-Y-G-K-G-L-I-N-V-

No: 275  
a) Q-A-A-A-Q  
g) E-A-A-A-Q

Fig. 2a

5/5




Fig. 3

SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> Subtilase enzymes of the I-S1 and I-S2 sub-groups  
having an additional amino acid residue in an active  
site loop region.

<130> 5692.204

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 275

<212> PRT

<213> Bacillus licheniformis

<400> 1

Ala Gln Thr Val Pro Tyr Gly Ile Pro Leu Ile Lys Ala Asp Lys Val  
1 5 10 15

Gln Ala Gln Gly Phe Lys Gly Ala Asn Val Lys Val Ala Val Leu Asp  
20 25 30

Thr Gly Ile Gln Ala Ser His Pro Asp Leu Asn Val Val Gly Gly Ala  
35 40 45

Ser Phe Val Ala Gly Glu Ala Tyr Asn Thr Asp Gly Asn Gly His Gly  
50 55 60

Thr His Val Ala Gly Thr Val Ala Ala Leu Asp Asn Thr Thr Gly Val  
65 70 75 80

Leu Gly Val Ala Pro Ser Val Ser Leu Tyr Ala Val Lys Val Leu Asn  
85 90 95

Ser Xaa Ser Gly Ser Gly Thr Tyr Ser Gly Ile Val Ser Gly Ile Glu  
100 105 110

Trp Ala Thr Thr Asn Gly Met Asp Val Ile Asn Met Ser Leu Gly Gly  
115 120 125

Pro Ser Gly Ser Thr Ala Met Lys Gln Ala Val Asp Asn Ala Tyr Ala

130 135 140

Arg Gly Val Val Val Val Ala Ala Ala Gly Asn Ser Gly Ser Ser Gly  
145 150 155 160

Asn Thr Asn Thr Ile Gly Tyr Pro Ala Lys Tyr Asp Ser Val Ile Ala  
165 170 175

Val Gly Ala Val Asp Ser Asn Ser Asn Arg Ala Ser Phe Ser Ser Val  
180 185 190

Gly Ala Glu Leu Glu Val Met Ala Pro Gly Ala Gly Val Tyr Ser Thr  
195 200 205

Tyr Pro Thr Ser Thr Tyr Ala Thr Leu Asn Gly Thr Ser Met Ala Ser  
210 215 220

Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Asn  
225 230 235 240

Leu Ser Ala Ser Gln Val Arg Asn Arg Leu Ser Ser Thr Ala Thr Tyr  
245 250 255

Leu Gly Ser Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Glu Ala  
260 265 270

Ala Ala Gln  
275

<210> 2

<211> 270

<212> PRT

<213> Bacillus lentus

<400> 2

Ala Gln Ser Val Pro Trp Gly Ile Ser Arg Val Gln Ala Pro Ala Ala  
1 5 10 15

His Asn Arg Gly Leu Thr Gly Ser Gly Val Lys Val Ala Val Leu Asp  
20 25 30

Thr Gly Ile Ser Thr His Pro Asp Leu Asn Ile Arg Gly Gly Ala Ser  
35 40 45

Phe Val Pro Gly Glu Pro Ser Thr Gln Asp Gly Asn Gly His Gly Thr  
50 55 60

His	Val	Ala	Gly	Thr	Ile	Ala	Ala	Leu	Asn	Asn	Ser	Ile	Gly	Val	Leu	65	70	75	80
Gly	Val	Ala	Pro	Ser	Ala	Glu	Leu	Tyr	Ala	Val	Lys	Val	Leu	Gly	Ala	85	90	95	
Xaa	Ser	Gly	Ser	Gly	Ser	Val	Ser	Ser	Ile	Ala	Gln	Gly	Leu	Glu	Trp	100	105	110	
Ala	Gly	Asn	Asn	Gly	Met	His	Val	Ala	Asn	Leu	Ser	Leu	Gly	Ser	Pro	115	120	125	
Ser	Pro	Ser	Ala	Thr	Leu	Glu	Gln	Ala	Val	Asn	Ser	Ala	Thr	Ser	Arg	130	135	140	
Gly	Val	Leu	Val	Val	Ala	Ala	Ser	Gly	Asn	Ser	Gly	Ala	Gly	Ser	Ile	145	150	155	160
Ser	Tyr	Pro	Ala	Arg	Tyr	Ala	Asn	Ala	Met	Ala	Val	Gly	Ala	Thr	Asp	165	170	175	
Gln	Asn	Asn	Asn	Arg	Ala	Ser	Phe	Ser	Gln	Tyr	Gly	Ala	Gly	Leu	Asp	180	185	190	
Ile	Val	Ala	Pro	Gly	Val	Asn	Val	Gln	Ser	Thr	Tyr	Pro	Gly	Ser	Thr	195	200	205	
Tyr	Ala	Ser	Leu	Asn	Gly	Thr	Ser	Met	Ala	Thr	Pro	His	Val	Ala	Gly	210	215	220	
Ala	Ala	Ala	Leu	Val	Lys	Gln	Lys	Asn	Pro	Ser	Trp	Ser	Asn	Val	Gln	225	230	235	240
Ile	Arg	Asn	His	Leu	Lys	Asn	Thr	Ala	Thr	Ser	Leu	Gly	Ser	Thr	Asn	245	250	255	
Leu	Tyr	Gly	Ser	Gly	Leu	Val	Asn	Ala	Glu	Ala	Ala	Thr	Arg			260	265	270	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00711

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 9/54 // C11D 3/386

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9927082 A1 (NOVO NORDISK A/S), 3 June 1999 (03.06.99), see claims --	1-34
A	WO 9530011 A2 (THE PROCTER & GAMBLE COMPANY), 9 November 1995 (09.11.95), see page 4, lines 12-21, page 13, lines 1-2 --	1-34
A	WO 9628566 A2 (THE PROCTER & GAMBLE COMPANY), 19 Sept 1996 (19.09.96), see claim 1 --	1-34
A	EP 0405901 A1 (UNILEVER NV), 2 January 1991 (02.01.91), see claim 1, page 45, line 44 and 50 --	1-34

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" other document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason has specified
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

31 March 2000

Date of mailing of the international search report

13-04-2000

Name and mailing address of the ISA

Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen/EÖ  
Telephone No. +46 8 782 25 00



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00711

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9855634 A1 (THE PROCTER & GAMBLE COMPANY), 10 December 1998 (10.12.98), see page 7, table 1  --	1-34
A	WO 9820115 A1 (NOVO NORDISK A/S), 14 May 1998 (14.05.98), see page 6, lines 6-8 and claims 7, 8 and 11  -- -----	1-34

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.  
PCT/DK 99/00711

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9927082	A1	03/06/99	AU	1225099	A	15/06/99
<hr/>							
WO	9530011	A2	09/11/95	AU	1253695	A	04/05/95
				AU	2294495	A	29/11/95
				AU	8079794	A	04/05/95
				BR	9407833	A	13/05/97
				BR	9407834	A	13/05/97
				BR	9507605	A	19/08/97
				CA	2173105	A	20/04/95
				CA	2173106	A	20/04/95
				CA	2189427	A	09/11/95
				CN	1137288	A	04/12/96
				CN	1137289	A	04/12/96
				CN	1151187	A	04/06/97
				CZ	9601052	A	11/09/96
				CZ	9601053	A	11/09/96
				CZ	9603217	A	14/05/97
				EP	0723579	A	31/07/96
				EP	0723580	A	31/07/96
				EP	0758389	A	19/02/97
				HU	75558	A	28/05/97
				HU	75984	A	28/05/97
				HU	76538	A	29/09/97
				HU	9600960	D	00/00/00
				HU	9600961	D	00/00/00
				HU	9603030	D	00/00/00
				JP	2888985	B	10/05/99
				JP	2888986	B	10/05/99
				JP	9503818	T	15/04/97
				JP	9505841	T	10/06/97
				JP	9512434	T	16/12/97
				JP	11246895	A	14/09/99
				JP	11246896	A	14/09/99
				US	5677272	A	14/10/97
				US	5679630	A	21/10/97
				US	5932532	A	03/08/99
				WO	9510591	A	20/04/95
				WO	9510592	A	20/04/95
<hr/>							
WO	9628566	A2	19/09/96	AU	4868896	A	02/10/96
				BR	9607356	A	15/06/99
				CA	2214348	A	19/09/96
				CN	1183119	A	27/05/98
				CZ	9702793	A	12/11/97
				EP	0813596	A	29/12/97
				HU	9800765	A	28/07/98
				IL	117266	D	00/00/00
				JP	11501812	T	16/02/99
				ZA	9601631	A	06/09/96
<hr/>							

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.  
PCT/DK 99/00711

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0405901 A1	02/01/91	CA 2034486 A JP 4500385 T US 5665587 A WO 9100334 A EP 0405902 A JP 4500384 T WO 9100335 A	27/12/90 23/01/92 09/09/97 10/01/91 02/01/91 23/01/92 10/01/91
WO 9855634 A1	10/12/98	NONE	
WO 9820115 A1	14/05/98	AU 4772697 A EP 0948610 A	29/05/98 13/10/99

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**